Clinical Trial

Luminal Fructose Kinetics (MARTINI Study)

Study acronym: MARTINI
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 6, 2024 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
In this study the investigators aim is to explore the dynamics of (small) intestinal fructose catabolism in humans and ethanol production in relation to small intestinal signalling pathways and changes in pH, using 13C fructose isotope tracing techniques complemented with direct luminal sampling via small intestinal catheter in biopsy proven MASLD/MASH patients vs healthy (BMI\<25) subjects. Additionally the investigators will repeat the experiment after four weeks of administering omeprazole at a dose of 40 mg twice daily. Omeprazole is a proton pump inhibitor, known to elevate pH from 2-6.
Trial Details
NCT Number NCT06539494
Lead Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions MASLD
Enrollment 22 participants
Start Date 2024-07-01
Primary Completion 2026-01 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2024-08-06